Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01639456 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01677949 | Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 |
| clinicaltrials |
| NCT02118311 | Treg Cells for AGVHD in Non-myeloablative UCB Transplant | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00983944 | Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma | withdrawn | Phase 2 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Nov 30, 2017 | clinicaltrials |
| NCT02947113 | Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC(HYPOLAN) | withdrawn | Phase 2 | 0 | The Netherlands Cancer InstituteOTHER | 0 | Nov 30, 2017 | clinicaltrials |
| NCT00005998 | Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT02719015 | Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT02298595 | Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Julie E. Bauman, MD, MPHOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | withdrawn | Phase 2 | 0 | West Virginia UniversityOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00101140 | Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 19, 2017 | clinicaltrials |
| NCT03143491 | Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN) | withdrawn | Phase 2 | 0 | DFB Soria, LLCINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT02342600 | SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) | withdrawn | Phase 2 | 0 | Sarcoma Alliance for Research through CollaborationOTHER | 0 | Oct 12, 2017 | clinicaltrials |
| NCT02987010 | Phase 2 Study of IDH305 in Low Grade Gliomas | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | Oct 11, 2017 | clinicaltrials |
| NCT01251172 | RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2017 | clinicaltrials |
| NCT02662296 | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02736123 | Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone | withdrawn | Phase 1 / Phase 2 | 0 | University of PittsburghOTHER | 1 | Sep 20, 2017 | clinicaltrials |
| NCT00837174 | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study(COMBOSTAT) | withdrawn | Phase 2 | 0 | The Methodist Hospital Research InstituteOTHER | 0 | Sep 19, 2017 | clinicaltrials |
| NCT02876081 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex(THEN) | withdrawn | Phase 2 | 0 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT02677948 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02924233 | Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Symphogen A/SINDUSTRY | 0 | Aug 28, 2017 | clinicaltrials |
| NCT03013387 | Dosimetry Guided PRRT With 90Y-DOTATOC | withdrawn | Phase 2 | 0 | Sue O'DorisioOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT01833767 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | withdrawn | Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma(MUKfourteen) | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT02663258 | A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)(ADAPTeM) | withdrawn | Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT00257335 | Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer | withdrawn | Phase 2 | 0 | Nilam RamsinghaniOTHER | 0 | Jul 31, 2017 | clinicaltrials |
| NCT02639234 | Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Gradalis, Inc.INDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT03042013 | A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jul 11, 2017 | clinicaltrials |
| NCT01095523 | Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | withdrawn | Phase 1 / Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT02495636 | Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jun 22, 2017 | clinicaltrials |
| NCT00637117 | Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma. | withdrawn | Phase 1 / Phase 2 | 0 | Baylor Research InstituteOTHER | 0 | Jun 12, 2017 | clinicaltrials |
| NCT02829840 | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 2, 2017 | clinicaltrials |
| NCT02735850 | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)(ImmunoSABR) | withdrawn | Phase 2 | 0 | Maastricht Radiation OncologyOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT02623920 | Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma(S-BR) | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT02766842 | Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) | withdrawn | Phase 2 | 0 | Johns Hopkins UniversityOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases(BOS3) | withdrawn | Phase 2 / Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)(MEGAN) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT03070691 | Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | withdrawn | Phase 2 / Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 10 | May 5, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02802163 | Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Apr 25, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02961816 | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 21, 2017 | clinicaltrials |
| NCT00978146 | Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors | withdrawn | Phase 2 | 0 | Children's Hospital of PhiladelphiaOTHER | 0 | Apr 20, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer(PRIMIER) | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2017source: clinicaltrials